Type 2 diabetes, skin autofluorescence, and brain atrophy

Diabetes

Volumn 64, Issue 1, 2015, Pages 279-283

  Moran, Chris ^a,b   Münch, Gerald ^c   Forbes, Josephine M ^d   Beare, Richard ^a,b,e   Blizzard, Leigh ^f   Venn, Alison J ^f   Phan, Thanh G ^a,b   Chen, Jian ^a,b,e   Srikanth, Velandai ^a,b,f  

^a Southern Clinical School   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^f UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE; BRAIN ATROPHY; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPERIMENTAL COGNITIVE TEST; FEMALE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN LOCALIZATION; SKIN; ATROPHY; BRAIN DISEASE; CROSS-SECTIONAL STUDY; FLUORESCENCE; METABOLISM; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATROPHY; BRAIN DISEASES; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FLUORESCENCE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SKIN;

EID: 84920059475     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0506     Document Type: Article

References (21)

1. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 2006;5:64-74
2. Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: Regional distribution and influence on cognition. Diabetes Care 2013;36:4036-4042
3. Bucala R, Cerami A. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992;23:1-34
4. Srikanth V, Westcott B, Forbes J, et al. Methylglyoxal, cognitive function and cerebral atrophy in older people. J Gerontol A Biol Sci Med Sci 2013;68:68-73
5. Yaffe K, Lindquist K, Schwartz AV, et al. Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology 2011;77:1351-1356
6. Meerwaldt R, Graaff R, Oomen PH, et al. Simple non-Invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-1330
7. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26:839-851
8. Wrench JM, Wilson SJ, Bladin PF, Reutens DC. Hippocampal volume and depression: Insights from epilepsy surgery. J Neurol Neurosurg Psychiatry 2009; 80:539-544
9. Ishibashi Y, Yamagishi S, Matsui T, et al. Pravastatin inhibits advanced glycation end products (AGEs)-Induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism 2012;61:1067-1072
10. Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-Induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010;61:34-39
11. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGEinduced proximal tubular cell injury. Pharmacol Res 2012;65:297-302
12. Srikanth V, Maczurek A, Phan T, et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011;32:763-777
13. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259
14. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 1994;91:4766-4770
15. Smith MA, Taneda S, Richey PL, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 1994;91:5710-5714
16. Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A 1994;91:7787-7791
17. Münch G, Westcott B, Menini T, Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids 2012; 42:1221-1236
18. Li XH, Lv BL, Xie JZ, Liu J, Zhou XW, Wang JZ. AGEs induce Alzheimer-Like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 2012;33:1400-1410
19. Takeuchi M, Bucala R, Suzuki T, et al. Neurotoxicity of advanced glycation endproducts for cultured cortical neurons. J Neuropathol Exp Neurol 2000;59:1094-1105
20. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907-913
21. Meerwaldt R, Hartog JW, Graaff R, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687-3693